Holen Sie sich die Stockscreener-App
1.98
0.50%
-0.01
Handel nachbörslich:
1.98
Schlusskurs vom Vortag:
$1.99
Offen:
$1.99
24-Stunden-Volumen:
1.17M
Relative Volume:
1.29
Marktkapitalisierung:
$266.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-101.70M
KGV:
-1.0442
EPS:
-1.8961
Netto-Cashflow:
$-84.35M
1W Leistung:
-2.46%
1M Leistung:
+16.47%
6M Leistung:
+38.46%
1J Leistung:
+313.45%
1-Tages-Spanne:
$1.945
$2.015
1-Wochen-Bereich:
$1.88
$2.07
52-Wochen-Spanne:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.98 | 267.78M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Eingeleitet | Wells Fargo | Overweight |
| 2026-03-06 | Fortgesetzt | UBS | Buy |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
Is ALX Oncology Holdings (ALXO) outperforming other medical stocks this year? - MSN
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Redmile Group, ALXO: Investment manager discloses 6.8% ownership - Stock Titan
HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake - Stock Titan
Earnings call transcript: ALX Oncology beats Q1 2026 earnings forecast - Investing.com
Q2 EPS Estimates for ALX Oncology Raised by HC Wainwright - MarketBeat
TradingKey - TradingKey
UBS Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q1 2026 Earnings Call Transcript - Insider Monkey
Alx Oncology Signals Promise, But Validation Looms - TipRanks
ALX Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS - MSN
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Moomoo
ALX Oncology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ALXO: ALX Oncology Reports Promising Data on CD47 Biomarker in H - GuruFocus
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings - Moomoo
ALX Oncology Holdings Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALXO) 2026-05-08 - Seeking Alpha
ALX Oncology Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: ALX Oncology Q1 2026 reveals clinical progress By Investing.com - Investing.com Canada
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology 1Q Loss/Shr 17c >ALXO - Moomoo
ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data - ChartMill
ALX Oncology Q1 2026 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings 1Q 2026: Net income $(17.9M), EPS $(0.17) — 10-Q Summary - TradingView
[10-Q] ALX ONCOLOGY HOLDINGS INC Quarterly Earnings Report - Stock Titan
ALX Oncology reports Q1 net loss of $17.9M, cash $169.1M; advances evorpacept and ALX2004 programs - TradingView
ALXO: Durable clinical responses and reduced net loss highlight progress in HER2-positive cancer trials - TradingView
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ALX Oncology (NASDAQ: ALXO) cuts Q1 loss, raises $150M for cancer pipeline - Stock Titan
ALX Oncology reports all 5 high-CD47 breast cancer patients responded - Stock Titan
ALX Oncology reports breast cancer trial data with CD47 biomarker - Investing.com UK
MSN Money - MSN
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - Investing News Network
ALX Oncology reports breast cancer trial data with CD47 biomarker By Investing.com - Investing.com Australia
Insiders Buying ALX Oncology Holdings Might Wish They Invested More, Stock Gains 32% - Moomoo
Alx Oncology's evorpacept in combination with zanidatamab generates promising, durable response in patients with advanced her2-positive breast cancer and high cd47 expression - marketscreener.com
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - The Manila Times
In ALX breast cancer study, 5 of 5 high-CD47 patients responded - Stock Titan
ALX Oncology’s Evorpacept in Combination with Zanidatamab - GlobeNewswire
ALX Oncology Holdings Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ALX Oncology (ALXO.US) will release its earnings report before the market opens on May 8. - Moomoo
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):